TrialBlood2025
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma.
Surbhi Sidana et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
21 papers cite it
this paperpooled itcites it
TrialBlood2025
Surbhi Sidana et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.